Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Chapple

Showing results (21-30 of 271) with videos related to

Pageof 28
Sort By:
European Urology|November 23, 2018
What Is the Current Role of β<sub>3</sub>-Adrenergic Receptor Agonists and How Do They Work?Christopher R Chapple
Nature Clinical Practice. Urology|February 14, 2006
Primer: questionnaires versus urodynamics in the evaluation of lower urinary tract dysfunction-one, both or none?Christopher R Chapple
Current Opinion in Urology|December 20, 2002
Clinical study of benign prostatic disease, current concepts and future prospects: randomized controlled trials versus real life practiceChristopher R Chapple
European Urology|May 2, 2009
Lower urinary tract symptoms revisitedChristopher R Chapple
European Urology|December 30, 2011
Which preparation of botulinum toxin a should be used, where should it be injected, and how should its efficacy be assessed?Christopher R Chapple
European Urology|July 9, 2013
Reply from author re: Stephan Madersbacher. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions. Eur Urol 2013;64:257-9: OnabotulinumtoxinA for idiopathic overactive bladder symptoms: some answers but even more questionsChristopher R Chapple
Current Opinion in Urology|October 2, 2013
A contemporary update on the management of male incontinenceChristopher R Chapple
Drugs in R&D|May 11, 2002
Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteersChristopher R Chapple, Lisbeth Nilvebrant
Expert Review of Clinical Pharmacology|December 22, 2016
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in AsiaChristopher R Chapple, Emad Siddiqui
Asian Journal of Andrology|October 9, 2012
Tissue engineering in urethral reconstruction--an updateAltaf Mangera, Christopher R Chapple
Pageof 28

Showing results (21-30 of 271) with videos related to

Sort By:
Pageof 28
European Urology|November 23, 2018
What Is the Current Role of β<sub>3</sub>-Adrenergic Receptor Agonists and How Do They Work?Christopher R Chapple
Nature Clinical Practice. Urology|February 14, 2006
Primer: questionnaires versus urodynamics in the evaluation of lower urinary tract dysfunction-one, both or none?Christopher R Chapple
Current Opinion in Urology|December 20, 2002
Clinical study of benign prostatic disease, current concepts and future prospects: randomized controlled trials versus real life practiceChristopher R Chapple
European Urology|May 2, 2009
Lower urinary tract symptoms revisitedChristopher R Chapple
European Urology|December 30, 2011
Which preparation of botulinum toxin a should be used, where should it be injected, and how should its efficacy be assessed?Christopher R Chapple
European Urology|July 9, 2013
Reply from author re: Stephan Madersbacher. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions. Eur Urol 2013;64:257-9: OnabotulinumtoxinA for idiopathic overactive bladder symptoms: some answers but even more questionsChristopher R Chapple
Current Opinion in Urology|October 2, 2013
A contemporary update on the management of male incontinenceChristopher R Chapple
Drugs in R&D|May 11, 2002
Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteersChristopher R Chapple, Lisbeth Nilvebrant
Expert Review of Clinical Pharmacology|December 22, 2016
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in AsiaChristopher R Chapple, Emad Siddiqui
Asian Journal of Andrology|October 9, 2012
Tissue engineering in urethral reconstruction--an updateAltaf Mangera, Christopher R Chapple
Pageof 28